Recon: Ironwood to buy VectivBio for $1B; FDA panel votes against recommending Intercept NASH drug
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy